Determinants of physical quality of life in patients with chronic thromboembolic pulmonary hypertension after treatment: Insights from invasive exercise stress test
Impaired quality of life (QoL) is prevalent among patients with chronic thromboembolic pulmonary hypertension (CTEPH) despite improved survival due to medical advances. We clarified the physical QoL of patients with CTEPH with mildly elevated pulmonary hemodynamics and evaluated its determinants using a database of patients with CTEPH evaluated for hemodynamics during exercise. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 16, 2024 Category: Transplant Surgery Authors: Kosuke Watabe, Ayumi Goda, Kazuki Tobita, Sachi Yokoyama, Hanako Kikuchi, Kaori Takeuchi, Takumi Inami, Kyoko Soejima, Takashi Kohno Source Type: research
Mildly elevated pulmonary vascular resistance and worsened survival in PH-ILD: an opportunity for earlier diagnosis and intervention?
Pulmonary hypertension (PH) is a feared complication of interstitial lung disease (ILD) owing to increased risk for hospitalisation and mortality among affected patients. The development of PH in ILD is attributed to several pathobiological mechanisms that often converge to remodel pulmonary arterioles including hypoxic pulmonary vasoconstriction, endothelial dysfunction, inflammation, increased oxidant stress and the pathogenic effects of parenchymal fibrosis on the alveolar-capillary interface.1 The classical definition of precapillary PH used a mean pulmonary arterial pressure (mPAP) ≥25 mm Hg and pulmonary vascular ...
Source: Thorax - April 15, 2024 Category: Respiratory Medicine Authors: Cassady, S. J., Maron, B. A. Tags: Thorax Editorial Source Type: research
Mild elevation of pulmonary vascular resistance predicts mortality regardless of mean pulmonary artery pressure in mild interstitial lung disease
Conclusions
Mild elevation of PVR was associated with a higher mortality rate in patients with newly diagnosed ILD, even in those with MPAP≤20 mm Hg. (Source: Thorax)
Source: Thorax - April 15, 2024 Category: Respiratory Medicine Authors: Sato, T., Furukawa, T., Teramachi, R., Fukihara, J., Yamano, Y., Yokoyama, T., Matsuda, T., Kataoka, K., Kimura, T., Sakamoto, K., Ishii, M., Kondoh, Y. Tags: Editor's choice, Thorax Interstitial lung disease Source Type: research
Is pulmonary hypertension protective against cardiac tamponade? A systematic review
AbstractThe presence of pulmonary hypertension (PH) may affect whether cardiac tamponade physiology develops from a pericardial effusion. Specifically, the increased intracardiac pressure and right ventricular hypertrophy associated with PH would seemingly increase the intrapericardial pressure threshold at which the right-sided chambers collapse. In this systematic review, we examined the impact of PH on the incidence, in-hospital and long-term mortality, and echocardiographic findings of patients with cardiac tamponade. Using the PRISMA guideline, a systematic search was conducted in PubMed, Academic Search Premier, Web ...
Source: Internal and Emergency Medicine - April 15, 2024 Category: Emergency Medicine Source Type: research
Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. Pulmonary hypertension due to left heart disease (PH-LHD) currently lacks targeted therapies, while Pulmonary arterial hypertension (PAH), despite approved treatments, carries considerable residual risk. Metabolic dysfunction has been linked to the pathogenesis and prognosis of PH through various studies, with emerging metabolic agents offering a potential avenue for improving patient outcomes. (Source: Respiratory Medicine)
Source: Respiratory Medicine - April 14, 2024 Category: Respiratory Medicine Authors: Taimin Luo, Hui Wu, Wanlong Zhu, Liaoyun Zhang, Yilan Huang, Xuping Yang Source Type: research
Non ‐canonical IKB kinases regulate YAP/TAZ and pathological vascular remodeling behaviors in pulmonary artery smooth muscle cells
AbstractPulmonary arterial hypertension (PAH) causes pulmonary vascular remodeling, increasing pulmonary vascular resistance (PVR) and leading to right heart failure and death. Matrix stiffening early in the disease promotes remodeling in pulmonary artery smooth muscle cells (PASMCs), contributing to PAH pathogenesis. Our research identified YAP and TAZ as key drivers of the mechanobiological feedback loop in PASMCs, suggesting targeting them could mitigate remodeling. However, YAP/TAZ are ubiquitously expressed and carry out diverse functions, necessitating a cell-specific approach. Our previous work demonstrated that tar...
Source: Physiological Reports - April 13, 2024 Category: Physiology Authors: Aja Aravamudhan,
Paul B. Dieffenbach,
Kyoung Moo Choi,
Patrick A. Link,
Jeffrey A. Meridew,
Andrew J. Haak,
Laura E. Fredenburgh,
Daniel J. Tschumperlin Tags: ORIGINAL ARTICLE Source Type: research
Atrial Fibrillation Ablation in Patients with Pulmonary Hypertension: Multicenter Experience
Pulmonary hypertension (PH) is a progressive condition characterized by pulmonary vascular remodeling and elevated pulmonary arterial pressure. Atrial arrhythmias are common in PH and may contribute to right ventricular failure and death1,2. We retrospectively identified patients with pre-capillary PH who underwent catheter ablation for AF at four high-volume ablation centers. Included patients had an established clinical diagnosis of PH, with suspected pre-capillary etiology, and at least one right heart catheterization showing mean pulmonary artery pressure>20 mm Hg and pulmonary capillary wedge pressure ≤15 mm Hg. (Source: Heart Rhythm)
Source: Heart Rhythm - April 13, 2024 Category: Cardiology Authors: Thomas A. Boyle, Bao Ha, Ikram Haq, Ammar Killu, Ritu Yadav, David Spragg, Christopher X. Wong, Babikir Kheiri, Joshua D. Moss, Francis E. Marchlinski, David S. Frankel Source Type: research
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era
CONCLUSIONS: Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs. This highlights the necessity for comprehensive reassessment during early follow-up. The use of pulmonary artery compliance in addition to current measures may better identify those likely to have a good long-term response.PMID:38606558 | DOI:10.1161/CIRCULATIONAHA.122.063821 (Source: Circulation)
Source: Circulation - April 12, 2024 Category: Cardiology Authors: Felix Gerhardt Eva Fiessler Karen M Olsson Moritz Z Kayser Gabor Kovacs Henning Gall H Ardeschir Ghofrani Roza Badr Eslam Irene M Lang Nicola Benjamin Ekkehard Gr ünig Michael Halank Tobias J Lange Silvia Ulrich Hanno Leuchte Matthias Held Hans Klose Ral Source Type: research
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era
CONCLUSIONS: Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs. This highlights the necessity for comprehensive reassessment during early follow-up. The use of pulmonary artery compliance in addition to current measures may better identify those likely to have a good long-term response.PMID:38606558 | DOI:10.1161/CIRCULATIONAHA.122.063821 (Source: Circulation)
Source: Circulation - April 12, 2024 Category: Cardiology Authors: Felix Gerhardt Eva Fiessler Karen M Olsson Moritz Z Kayser Gabor Kovacs Henning Gall H Ardeschir Ghofrani Roza Badr Eslam Irene M Lang Nicola Benjamin Ekkehard Gr ünig Michael Halank Tobias J Lange Silvia Ulrich Hanno Leuchte Matthias Held Hans Klose Ral Source Type: research
Take-home messages from the 2nd COPD 2023 Biennial of the French Society of Respiratory Diseases. Placing the patient at the center of the care pathway
CONCLUSIONS: As regards COPD, a personalized approach is crucial, placing the patient at the center of the care pathway and facilitating coordination between healthcare providers.PMID:38609767 | DOI:10.1016/j.rmr.2024.03.008 (Source: Revue des Maladies Respiratoires)
Source: Revue des Maladies Respiratoires - April 12, 2024 Category: Respiratory Medicine Authors: J Ancel E Chen A Pavot L Regard O Le Rouzic M Guecamburu M Zysman A Rapin C Martin T Soumagne M Patout N Roche G Deslee Source Type: research
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era
CONCLUSIONS: Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs. This highlights the necessity for comprehensive reassessment during early follow-up. The use of pulmonary artery compliance in addition to current measures may better identify those likely to have a good long-term response.PMID:38606558 | DOI:10.1161/CIRCULATIONAHA.122.063821 (Source: Circulation)
Source: Circulation - April 12, 2024 Category: Cardiology Authors: Felix Gerhardt Eva Fiessler Karen M Olsson Moritz Z Kayser Gabor Kovacs Henning Gall H Ardeschir Ghofrani Roza Badr Eslam Irene M Lang Nicola Benjamin Ekkehard Gr ünig Michael Halank Tobias J Lange Silvia Ulrich Hanno Leuchte Matthias Held Hans Klose Ral Source Type: research
Take-home messages from the 2nd COPD 2023 Biennial of the French Society of Respiratory Diseases. Placing the patient at the center of the care pathway
CONCLUSIONS: As regards COPD, a personalized approach is crucial, placing the patient at the center of the care pathway and facilitating coordination between healthcare providers.PMID:38609767 | DOI:10.1016/j.rmr.2024.03.008 (Source: Revue des Maladies Respiratoires)
Source: Revue des Maladies Respiratoires - April 12, 2024 Category: Respiratory Medicine Authors: J Ancel E Chen A Pavot L Regard O Le Rouzic M Guecamburu M Zysman A Rapin C Martin T Soumagne M Patout N Roche G Deslee Source Type: research
Take-home messages from the 2nd COPD 2023 Biennial of the French Society of Respiratory Diseases. Placing the patient at the center of the care pathway
CONCLUSIONS: As regards COPD, a personalized approach is crucial, placing the patient at the center of the care pathway and facilitating coordination between healthcare providers.PMID:38609767 | DOI:10.1016/j.rmr.2024.03.008 (Source: Respiratory Care)
Source: Respiratory Care - April 12, 2024 Category: Respiratory Medicine Authors: J Ancel E Chen A Pavot L Regard O Le Rouzic M Guecamburu M Zysman A Rapin C Martin T Soumagne M Patout N Roche G Deslee Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferati...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
NGF increases Connexin-43 expression and function in pulmonary arterial smooth muscle cells to induce pulmonary artery hyperreactivity
CONCLUSIONS: Modulation of Cx43 by NGF in pulmonary arterial smooth muscle cells contributes to NGF-induced alterations of pulmonary artery reactivity. Since NGF and its TrkA receptor play a role in vivo in Cx43 increased expression in PH induced by chronic hypoxia, these NGF/Cx43-dependent mechanisms may therefore play a significant role in human PH pathophysiology.PMID:38599061 | DOI:10.1016/j.biopha.2024.116552 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 10, 2024 Category: Drugs & Pharmacology Authors: Guillaume Cardouat Matthieu Douard Cl ément Bouchet Lukas Roubenne Zuzana Kmecov á Pauline Esteves Fabien Brette Christophe Guignabert Ly Tu Marilyne Campagnac Paul Robillard Florence Coste Fr édéric Delcambre Matthieu Thumerel Hugues Begueret Arnaud Source Type: research
